Biotech VCs ramp up checks on new bets after years of focusing on existing portfolios
Biotech VCs ramp up checks on new bets after years of focusing on existing portfolios
暂时没有全文，请查看原始来源。
目录
59 全部
Thermo Fisher
资讯 
Danaher
资讯 
Agilent
资讯 
Merck KGaA
资讯 
Illumina
资讯 
Waters
资讯 
Bruker
资讯 
Sartorius
资讯 
Mettler Toledo
资讯 
PerkinElmer (Revvity)
资讯 
Bio-Rad
资讯 
Carl Zeiss
资讯 
Nikon
资讯 
Eppendorf
资讯 
Corning
资讯 
BD (Becton Dickinson)
资讯 
Qiagen
资讯 
MGI Tech (华大智造)
资讯 
Haier Biomedical
资讯 
Lonza
资讯 
WuXi AppTec (药明康德)
资讯 
WuXi Biologics
资讯 
Charles River
资讯 
Catalent
资讯 
Samsung Biologics
资讯 
IQVIA
资讯 
LabCorp
资讯 
Eurofins
资讯 
Pharmaron (康龙化成)
资讯 
Pfizer
资讯 
Roche
资讯 
Merck & Co. (MSD)
资讯 
Novartis
资讯 
Eli Lilly
资讯 
Novo Nordisk
资讯 
Moderna
资讯 
BioNTech
资讯 
Amgen
资讯 
BeiGene (百济神州)
资讯 
Vertex
资讯 
Schrödinger
资讯 
Recursion
资讯 Exscientia
资讯 
Insilico Medicine
资讯 
XtalPi (晶泰科技)
资讯 
NVIDIA Healthcare
资讯 
DeepMind (Google)
资讯 
Medtronic
资讯 
Siemens Healthineers
资讯 
GE HealthCare
资讯 
Philips
资讯 
Abbott
资讯 
Intuitive Surgical
资讯 
Boston Scientific
资讯 
Edwards Lifesciences
资讯 
Mindray (迈瑞)
资讯 
United Imaging (联影)
资讯 
Sysmex
资讯 
Hologic
资讯